Kozak & Associates’s Health Catalyst HCAT Stock Holding History

Kozak & Associates’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-405	Closed	-$6K	–	353
2022 Q2	$6K	Hold	405	–	–	﹤0.01%	276
2022 Q1	$10K	Hold	405	–	–	0.01%	252
2021 Q4	$10K	Hold	405	–	–	0.01%	252
2021 Q3	$20K	Buy	+405	New	+$22.1K	0.01%	206

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Kozak & Associates's HCAT Position: Q3 2022 in Review

Kozak & Associates sold out of Health Catalyst (HCAT) in Q3 2022, closing a stake of 405 shares — an estimated $6K sold.

Kozak & Associates first reported a position in HCAT in Q3 2021 and held it in 4 quarters. The position peaked at $20K in Q3 2021. 171 funds tracked by Wall St. Rank hold HCAT as of Q3 2022.

Kozak & Associates reported no remaining Health Catalyst position as of Q3 2022 after selling out during the quarter.
Kozak & Associates sold 405 Health Catalyst shares in Q3 2022, an estimated $6K.
Kozak & Associates first reported a position in Health Catalyst in Q3 2021 and held it in 4 quarters.
Kozak & Associates's Health Catalyst position peaked at $20K in Q3 2021.
171 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2022.

Based on Kozak & Associates's 13F filing for Q3 2022, filed 12 Oct 2022.